Previous 10 | Next 10 |
Image source: The Motley Fool. Theravance Biopharma Inc (NASDAQ: TBPH) Q3 2019 Earnings Call Nov 5, 2019 , 5:00 p.m. ET Operator Continue reading
Theravance Biopharma (NASDAQ: TBPH ): Q3 GAAP EPS of -$1.05 beats by $0.03 . More news on: Theravance Biopharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
DUBLIN , Nov. 5, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the third quarter ended September 30, 2019 . Revenue for the third quarter of 2019 was $12.4 million . Third quarter operating l...
DUBLIN , Oct. 29, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended September 30, 2019 and provide a business update after market close on Tuesday, No...
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Oct. 21, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today announced that data from studies of YUPELRI ® (r...
Yesterday, investors discovered the likely reason for the strange recent weakness in Theravance ( TBPH ), despite the neutral or even good news flow: Neil Woodford has been ousted and his flagship fund - which holds the bulk of his large TBPH stake - will be liquidated by BlackRock: "bec...
DUBLIN , Sept. 25, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will participate in a fireside chat at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 , at 7:45 a.m. ET . The conference will take place Oct...
Initial data from a Phase 1 clinical trial evaluating single and multiple ascending doses of Theravance Biopharma's ( TBPH -0.1% ) inhalable JAK inhibitor TD-8236 in healthy volunteers and patients with mild asthma showed a favorable safety profile. More news on: Theravance Biopharm...
DUBLIN , Sept. 9, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced initial results, including positive biomarker responses, from its Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical ...
I have always found that mercy bears richer fruits than strict justice ." - Abraham Lincoln We continue our series of reviews of Q2 results at previously profiled small biotech concerns today. In today's post, we revisit Theravance Biopharma ( TBPH ) whose stock has been on a nice little ...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...